Are Peptides Legal in Delaware? (2026)

The federal rules that apply in Delaware, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Delaware:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Delaware. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Delaware law adds

Delaware's controlled-substances law (16 Del. C. § 4701 et seq. (Uniform Controlled Substances Act); Schedule III at § 4718) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (delcode.delaware.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Delaware's schedules or in a Delaware-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Neither growth hormone nor gonadotropin appears in Delaware's Schedule III or elsewhere in the schedules. Section 4701(21) oddly defines human growth hormone as synonymous with human chorionic gonadotropin, but the term is not used in any schedule. Section 4757(a)(7) bars prescribing anabolic steroids for muscle building or performance. (16 Del. C. § 4718 (Schedule III); § 4757(a)(7)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

No Delaware Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Delaware pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Delaware medical board guidance specific to peptide therapy was located. A Delaware prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Delaware

No Delaware provision specific to research peptides was found; the federal rules apply. (delcode.delaware.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Delaware is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Under 24 Del. C. §§ 6001 to 6005 a provider must, before diagnosis or treatment, examine the patient in person, have another Delaware-licensed provider present, diagnose by audio-visual communication, or meet applicable professional-society standards; prescriptions may not be issued solely on an internet questionnaire or a phone consultation without a relationship. An interstate telehealth registration is available. (delcode.delaware.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Delaware law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in Delaware

The Bureau found no Delaware-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. No Delaware Board of Pharmacy or Board of Medical Licensure statement on compounded GLP-1s or peptides was found.

Frequently asked questions

Is BPC-157 legal in Delaware?

Delaware has not scheduled BPC-157, so possessing it is not a Delaware offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Delaware?

Yes. Under 24 Del. C. §§ 6001 to 6005 a provider must, before diagnosis or treatment, examine the patient in person, have another Delaware-licensed provider present, diagnose by audio-visual communication, or meet applicable professional-society standards; prescriptions may not be issued solely on an internet questionnaire or a phone consultation without a relationship. An interstate telehealth registration is available. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Delaware?

Only with a valid prescription for an approved use. Delaware does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://delcode.delaware.gov/title16/c047/sc01/index.html
• https://codes.findlaw.com/de/title-16-health-and-safety/de-code-sect-16-4718.html
• https://delcode.delaware.gov/title24/c060/index.html

Every Delaware fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.